Advanced in Histiocytosis
Advanced in Histiocytosis
254 Easton Ave, 
New Brunswick, NJ 

Overview

Nibal Zaghloul is a Pediatric Hematologist Oncology provider in New Brunswick, New Jersey. Dr. Zaghloul is rated as an Advanced provider by MediFind in the treatment of Histiocytosis. His top areas of expertise are Histiocytosis, Reticulohistiocytoma, Langerhans Cell Histiocytosis, Intersex, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 31 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 10 clinical trials in the study of Histiocytosis.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

254 Easton Ave, New Brunswick, NJ 08901

Additional Areas of Focus

Dr. Zaghloul has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


31 Clinical Trials

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
View 30 Less Clinical Trials
Similar Doctors
Distinguished in Histiocytosis
Pediatric Hematology Oncology
Distinguished in Histiocytosis
Pediatric Hematology Oncology
211 Clinton St, Apt 2c, 
Brooklyn, NY 
 (29.7 miles away)
Languages Spoken:
English

Nitya Gulati is a Pediatric Hematologist Oncology provider in Brooklyn, New York. Dr. Gulati is rated as an Advanced provider by MediFind in the treatment of Histiocytosis. Her top areas of expertise are Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Non-Langerhans-Cell Histiocytosis.

Distinguished in Histiocytosis
Pediatric Hematology Oncology
Distinguished in Histiocytosis
Pediatric Hematology Oncology
1275 York Ave, 
New York, NY 
 (34.3 miles away)
Languages Spoken:
English

Ira Dunkel is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Dunkel is rated as an Elite provider by MediFind in the treatment of Histiocytosis. His top areas of expertise are Retinoblastoma, Diffuse Midline Glioma H3 K27M-Mutant, Glioma, and Brain Stem Cancer.

Advanced in Histiocytosis
Pediatric Hematology Oncology
Advanced in Histiocytosis
Pediatric Hematology Oncology
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, 
Philadelphia, PA 
 (52.1 miles away)
Languages Spoken:
English

David Teachey is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Teachey is rated as an Elite provider by MediFind in the treatment of Histiocytosis. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Adult T-Cell Leukemia, Leukemia, Multisystem Inflammatory Syndrome in Children (MIS-C), and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zaghloul's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile